TUBULIS
Tubulis develops chemotherapeutic medications to combat cancer and chronic disorders. The company's chemotherapeutic medications are specifically matched protein-drug conjugates created by merging proprietary innovative technology with disease-specific biology, allowing clinicians to treat cancer patients without the risks associated with chemotherapy.
TUBULIS
Industry:
Biotechnology Health Care Life Science Pharmaceutical Therapeutics
Founded:
2012-01-01
Address:
Munich, Bayern, Germany
Country:
Germany
Website Url:
http://www.tubulis.com
Total Employee:
11+
Status:
Active
Total Funding:
200 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon WordPress Organization Schema Sitelinks Search Box Yoast WordPress SEO Plugin Person Schema Facebook Sharer
Similar Organizations
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tesu Health
Tesu Health offers digital therapeutics for chronic diseases, focusing on non-chemical, non-biological treatments.
Current Advisors List
Board_member
2022-05-01
Board_member
Board_member
2022-05-01
Board_member
2022-05-01
Board_member
2022-05-01
Board_member
2022-05-01
Board_observer
2020-04-01
Board_member
Current Employees Featured
Ingo Lehrke CBO @ Tubulis
CBO
Dominik Schumacher Founder, CEO @ Tubulis
Founder, CEO
Björn Hock Chief Development Officer @ Tubulis
Chief Development Officer
2023-01-01
Jonas Helma Founder, CSO @ Tubulis
Founder, CSO
Founder
Investors List
coparion
coparion investment in Series B - Tubulis
OCCIDENT
OCCIDENT investment in Series B - Tubulis
Evotec
Evotec investment in Series B - Tubulis
BioMedPartners
BioMedPartners investment in Series B - Tubulis
Bayern Kapital
Bayern Kapital investment in Series B - Tubulis
Frazier Life Sciences
Frazier Life Sciences investment in Series B - Tubulis
Fund+
Fund+ investment in Series B - Tubulis
Seventure Partners
Seventure Partners investment in Series B - Tubulis
Nextech Invest
Nextech Invest investment in Series B - Tubulis
HTGF | High-Tech Gruenderfonds
HTGF | High-Tech Gruenderfonds investment in Series B - Tubulis
Key Employee Changes
| Date | New article |
|---|---|
| 2023-02-16 | Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer |
Official Site Inspections
http://www.tubulis.com Semrush global rank: 3.11 M Semrush visits lastest month: 4.93 K
- Host name: dd40828.kasserver.com
- IP address: 85.13.131.146
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Tubulis"
Tubulis - Crunchbase Company Profile & Funding
Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment.See details»
Startseite - Tubulis
Jan 30, 2025 Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models.See details»
Meet the Team behind Tubulis - Tubulis
We are supported by a strong scientific and entrepreneurial network Together, the team has built a strong collaborative network bringing together expertise in chemistry, antibody technologies, …See details»
Org Chart Tubulis - The Official Board
The org chart of Tubulis contains its 32 main executives including Dominik Schumacher, Matthew Norkunas and Michael Wenzel.See details»
Tubulis Company Profile - Office Locations, Competitors ... - Craft
Tubulis has 5 employees at their 1 location and $13.72 m in total funding,. See insights on Tubulis including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Tubulis Technologies - VentureRadar
"Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of …See details»
Tubulis (Tubulis GmbH) - Startbase
Reimagining Antibody Drug Conjugates Protein-drug conjugates by combining proprietary novel technologies with disease-specific biology.See details»
Tubulis GmbH, Financial Info, Board and Management, …
SECTOR Super-Sector: Health CareSector: Health Care Equipment & ServicesSub-Sector: Medical Equipment KEY FIGURES Changes In Board and Management in last 6 months: …See details»
Be part of a multidisciplinary and dedicated team
The main goal of Tubulis is to become a leading company in the field of targeted therapeutics. With a strong team, our own technologies and innovative therapeutic concepts, we are ushering in a new era in the ongoing fight …See details»
Tubulis Company Information - Funding, Investors, and More
Tubulis has notable potential in developing chemotherapeutic drugs targeting cancer and chronic diseases. Based in Munich, the company focuses on innovative drug development to address …See details»
Tubulis - Funding, Financials, Valuation & Investors - Crunchbase
Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment.See details»
Tubulis | Falling Walls
Tubulis develops antibody-drug conjugates (ADCs) for the targeted therapy of cancer diseases with the aim of opening up new avenues in the treatment of tumors and providing patients with …See details»
Tubulis GmbH - Drug pipelines, Patents, Clinical trials - Synapse
Tubulis utilizes a blend of innovative proprietary technologies and disease-specific expertise to create tailored protein-drug conjugates. Their mission is to enhance the therapeutic …See details»
Tubulis GmbH | Insights
Dec 3, 2024 Rising Leaders Home As a schoolboy, Dominik Schumacher loved science. As CEO of Tubulis GmbH , from very early on he was always on the lookout for commercial …See details»
Tubulis announces Matthew Norkunas as CFO · Tubulis News
Feb 6, 2025 Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc.See details»
Tubulis (Tubulis GmbH) - Startbase
Reimagining Antibody Drug Conjugates Protein-Wirkstoff-Konjugate durch die Kombination proprietärer neuartiger Technologien mit krankheitsspezifischer Biologie.See details»
EQT Life Sciences Leads Tubulis’ Upsized €128 Million Series B2 …
Mar 14, 2024 Amsterdam, Netherlands, March 14, 2024 – EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Tubulis, which is developing a pipeline of …See details»
Tubulis - Contacts, Employees, Board Members, Advisors & Alumni
Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment.See details»
Tubulis | The Pharmaletter
Tubulis is advancing its proprietary pipeline of uniquely-assembled ADCs towards clinical evaluation as well as to introduce programs addressing a range of solid tumor indications. The …See details»
CEO at 33, Tubi's Anjali Sud on success hacks she learned at …
4 hours ago Anjali Sud, CEO of Fox streaming app Tubi, doesn't stay up late worrying about Netflix. She gets lots of sleep, and sees in her dreams a future of free TV.See details»